(Q35061729)

6 August 2017

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report (English)

1 reference

6 August 2017

1 reference

lymphoblastic leukemia

1 reference

Alice L Yu

2

0 references

author name string

Anne L Angiolillo

1

1 reference

6 August 2017

Gregory Reaman

3

1 reference

6 August 2017

Ashish M Ingle

4

1 reference

6 August 2017

Rita Secola

5

1 reference

6 August 2017

Peter C Adamson

6

1 reference

6 August 2017

1 December 2009

1 reference

6 August 2017

Pediatric Blood Cancer

1 reference

6 August 2017

53

1 reference

6 August 2017

6

1 reference

6 August 2017

978-983

1 reference

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

The gap between effect of drugs and effectiveness of treatments

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Epidemiology of hematological malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Childhood acute lymphoblastic leukaemia and relapse

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Pharmacokinetics of CAMPATH-1H: assay development and validation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120889

Activity of alemtuzumab in patients with CD52-positive acute leukemia

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19637330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19637330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acute lymphoblastic leukaemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19637330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PBC.22209

1 reference

6 August 2017

1 reference

6 August 2017

1 reference